Isis wins $ 1 million payment from GSK related to the advancement of ISIS-TTRRx -
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today ' hui she won a stage of $ 1 million payment from GlaxoSmithKline (GSK) related to the progress of the phase 2/3 ISIS-TTR Rx in patients with amyloid polyneuropathy family (FAP).
ISIS-TTR Rx is an antisense drug in development with GSK for the treatment of transthyretin amyloidosis, a severe and rare genetic disease characterized by progressive dysfunction of peripheral nerve / or cardiac tissues. Including this milestone payment, Isis has generated $ 27 million in upfront and milestone payments for advancing ISIS-TTR Rx . This milestone payment of $ 1 million is the fifth of the nearly $ 58 million in payments Isis step is eligible to win the Phase 2/3 study progresses. Additionally, if GSK chooses to exercise its exclusive option ISIS-TTR Rx program, Isis is eligible to receive royalties, payments and regulatory steps in sales and double-digit royalties on sales of ISIS TTR Rx .
The Phase 2/3 ISIS-TTR Rx is a double-blind, placebo-controlled, randomized international study designed to support a marketing authorization application market ISIS-TTR Rx in patients with FAP. The fifteen-month study will measure the effects of ISIS-TTR Rx on neurological dysfunction and on quality of life. ISIS-TTR Rx is an investigational drug that is designed to inhibit the production of all forms of TTR and treat all types of transthyretin amyloidosis related. For more information about the study, please visit www.clinicaltrials.gov and search for NCT01737398 ID.
EmoticonEmoticon